The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | NADIM: baseline ctDNA as a prognostic factor for PFS
Mariano Provencio, MD, PhD, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, outlines the relationship between high levels of baseline circulating tumor DNA (ctDNA) and progression-free survival (PFS) in patients who are receiving neoadjuvant chemoimmunotherapy in the NADIM clinical trial (NCT03081689). Analysis of 42 pre-treatment plasma samples from patients with NSCLC who were treated with nivolumab in the NADIM trial reported that ctDNA levels at mutant allele frequency below 1% at baseline were associated with improved PFS. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
